pentostatin
information and resources from the National Cancer Institute
NCI Thesaurus | pentostatin
A purine nucleotide analogue antibiotic isolated from the bacterium Streptomyces antibioticus. Also known as 2'-deoxycoformycin, pentostatin binds to and inhibits adenine deaminase (ADA), an enzyme essential to purine metabolism; ADA activity is greatest in cells of the lymphoid system with T-cells having higher activity than B-cells and T-cell malignancies higher ADA activity than B-cell malignancies. Pentostatin inhibition of ADA appears to result in elevated intracellular levels of dATP which may block DNA synthesis through the inhibition of ribonucleotide reductase. This agent may also inhibit RNA synthesis and may selectively deplete CD26+ lymphocytes. NCI Thesaurus | pentostatin
A purine nucleotide analogue antibiotic isolated from the bacterium Streptomyces antibioticus. Also known as 2'-deoxycoformycin, pentostatin binds to and inhibits adenine deaminase (ADA), an enzyme essential to purine metabolism; ADA activity is greatest in cells of the lymphoid system with T-cells having higher activity than B-cells and T-cell malignancies higher ADA activity than B-cell malignancies. Pentostatin inhibition of ADA appears to result in elevated intracellular levels of dATP which may block DNA synthesis through the inhibition of ribonucleotide reductase. This agent may also inhibit RNA synthesis and may selectively deplete CD26+ lymphocytes.
Nipent
Single agent treatment for adult patients with alpha interferon refractory hairy cell leukemia.
Parke-Davis Pharmaceutical Co. Oct 11 1991
Nipent
Single-agent treatment for untreated hairy cell leukemia patients with active disease as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms. (Supplement for front -line therapy.)
Parke-Davis Pharmaceutical Co. Sep 29 1993
|
|
|
|
news articles
Pentostatin, Cyclophosphamide, Rituxan® Active in Chronic ... Mar 10, 2006
Cancer Consultants (press release), ...article published in the Journal of Clinical Oncology, the treatment combination consisting of the chemotherapy agents pentostatin (Nipent®), cyclohpsophamide ...
Supergen Announces Results from Combination Study in Cll Published ... Mar 14, 2006
PharmaLive.com (press release), NASDAQ:SUPG) announced today that an article entitled, "Pentostatin, Cyclophosphamide, and Rituximab Is an Active, Well-Tolerated Regimen for Patients With ...
SuperGen Announces Results From Combination Study in CLL Published ... Mar 14, 2006
PR Newswire (press release), DUBLIN, Calif., March 14 /PRNewswire-FirstCall/ -- SuperGen, Inc. (Nasdaq: SUPG) announced today that an article entitled, "Pentostatin, Cyclophosphamide, and ...
SuperGen Reports Results From Combination Study In CLL Published ... Mar 14, 2006
Trading Markets, ...of Clinical Oncology showed higher response rates and similar or less toxicity using a three-drug combination therapy of pentostatin, cyclophosphamide and ...
SUPG: Nipent Studies Presented at ASH Dec 9, 2005
PharmaLive.com (press release), ...(Nasdaq: SUPG) announced that abstracts from five studies of its anticancer drug Nipent® (pentostatin for injection) will be presented this week during the ...
Studies of Nipent(R) in Combination Cancer Therapies for Treatment ... Dec 9, 2005
PR Newswire (press release), 9 /PRNewswire-FirstCall/ -- SuperGen, Inc. (Nasdaq: SUPG) announced that abstracts from five studies of its anticancer drug Nipent(R) (pentostatin for injection ...
Studies of Nipent in Combination Cancer Therapies for Treatment of ... Dec 9, 2005
PharmaLive.com (press release), ...announced that abstracts from five studies of its anticancer drug Nipent(R) (pentostatin for injection) will be presented this week during the proceedings of ...
Studies of Nipent(R) in Combination Cancer Therapies for Treatment ... Dec 12, 2005
Drug Newswire (press release), DUBLIN, Calif. — SuperGen, Inc. (NASDAQ:SUPG) announced that abstracts from five studies of its anticancer drug Nipent(R) (pentostatin for injection) will be ...
Dacogen(TM) (Decitabine) Injection Complete Response Accepted for ... Dec 15, 2005
Genetic Engineering News, Orathecin(TM) (rubitecan) capsules, an investigational drug being evaluated for the treatment of pancreatic cancer; Nipent(R) (pentostatin for injection ...
Nipent®/Cytoxan®/Rituxan® Shows High Activity in High-Risk ... Nov 23, 2005
Cancer Consultants (press release), ...from Ohio State University and the Mayo Clinical have reported that the treatment combination consisting of Nipent (pentostatin), Cytoxan (cyclophosphamide ...
SuperGen to Present at First Albany Capital Annual Growth ... Dec 5, 2005
PR Newswire (press release), SuperGen's product portfolio includes Nipent(R) (pentostatin for injection); Mitomycin (generic brand of Mutamycin(R)); and SurfaceSafe(R) cleaner. ...
|
|
